Technology ID

Peptide Vaccines Against Group A Streptococci

Linked ID
Bernard Beall (CDC)
Edwin Ades (CDC)
George Carlone (CDC)
Jacquelyn Sampson (CDC)
Lead Inventors
Bernard Beall (CDC)
Edwin Ades (CDC)
George Carlone (CDC)
Jacquelyn Sampson (CDC)
Development Status
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)
Therapeutic Areas
Infectious Disease
Commercial Applications
  • Group A streptococci (GAS) vaccine
  • GAS therapeutics and diagnostics
  • Lab tools for exploring GAS
This invention relates to synthetic immunoreactive peptides, which are portions of the M proteins of the most prevalent Group A Streptococcus (GAS) serotypes in the United States. These peptides may be useful in development of a flexible, multivalent GAS vaccine. They can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies. Additionally, the peptides or isolated antibodies raised in response to the peptides may be useful for GAS diagnostics.
Competitive Advantages
  • Easily adaptable to kit form
  • Multivalent vaccine that can be tailored for protection against specific GAS serotypes affecting a particular population

Request More Info

Licensing Contact